Key Takeaways
- Greece’s new CBD legislation mandates products to contain ‘exclusively cannabidiol (CBD),’ impacting not only THC but also other cannabinoids like CBG and CBC.
- The change from a loose framework to strict exclusivity may disadvantage small and mid-sized hemp producers, who rely on full-spectrum extracts.
- Industry experts warn that the ambiguous enforcement of ‘exclusively CBD’ could render many existing products non-compliant without clear guidelines.
- The legislative shift may favor large, well-capitalized producers who can efficiently create CBD isolate over smaller operations struggling to adapt.
- This ‘Greece CBD crackdown’ reflects a broader trend in Europe, narrowing compliance possibilities for the hemp market.
Last week, we covered how Circular AP oik.4941 dismantled Greece’s 0.3% THC threshold as a safe harbor for retailers. That story centered on THC. But a second, less obvious consequence is now surfacing, and it has nothing to do with getting high.
New industry analysis points to a phrase buried in Greece’s July legislation: products must contain “exclusively cannabidiol (CBD).” That’s a narrow definition, and it doesn’t just squeeze out THC. It potentially squeezes out CBG, CBC, CBN, and any other cannabinoid the hemp plant naturally produces alongside CBD.
What Does “Exclusively CBD” Actually Exclude?
Greece’s prior legal framework was comparatively loose. It covered products derived from Cannabis sativa varieties containing up to 0.3% THC, plus a general allowance for CBD-based goods. That gave manufacturers room to sell full-spectrum oils, the kind containing trace THC alongside CBD and minor cannabinoids like CBG, CBC, and CBN.
The July law replaced that flexibility with a category defined by exclusivity. A product either contains CBD and only CBD, or it doesn’t qualify.
Greek organic hemp producer KANNABIO, interviewed by HempToday, says its full-spectrum extracts typically test below 0.2% THC, while its broad-spectrum products (formulated without THC but retaining other cannabinoids) show quantifiable traces below 0.05%. Under a literal reading of “exclusively,” neither formulation clears the bar. The company says some products will likely be reformulated using CBD isolate instead of natural extracts.
Even that fix has a wrinkle. Highly purified, plant-derived CBD can still carry minute traces of other cannabinoids left over from extraction. Nobody has said yet how literally regulators will enforce the word “exclusively,” and that ambiguity is exactly the problem.
Why Would CBG and Minor Cannabinoids Get Caught in This Too?
CBG has spent the past few years becoming the hemp industry’s answer to a shrinking conventional CBD market. As CBD sales plateaued, companies leaned on CBG, CBN, and other minor cannabinoids to differentiate products and chase new customer interest.
Greece’s new wording may cut that path off entirely. According to legal analysis cited by HempToday, broad-spectrum extracts and CBG-based formulations fall outside the “exclusively CBD” definition simply because they contain cannabinoids other than CBD, regardless of whether any THC shows up on a lab report.
That’s worth sitting with. This isn’t a rule targeting intoxication. CBG isn’t psychoactive. A broad-spectrum tincture with zero detectable THC isn’t a public safety risk in any conventional sense. Yet if the “exclusively CBD” language gets enforced at face value, that product could be treated the same as one containing trace THC.
Prescription cannabinoid medicines aren’t part of this conversation. Pharmaceutical CBD products like Epidyolex, along with Greece’s broader medical cannabis system, operate under a separate regulatory track and remain unaffected.
Who Wins If the Plant Has to Be Stripped Down?
Here’s where the commercial stakes come into focus. Michalis Theodoropoulos, founder and CEO of KANNABIO, when speaking with HempToday,: “The Minister of Health is setting Greece back 15 years in terms of regulating the legal cannabis market, while creating conditions of unfair competition and monopolistic exploitation for the benefit of specific business interests.”
His argument is straightforward. Small and mid-sized hemp producers built their businesses around natural, full-spectrum extraction. That’s their product, their investment, and their point of differentiation. If the market shifts toward CBD isolate, the companies best positioned to win are the ones with the capital and lab infrastructure to produce ultra-purified isolate at scale, not the regional producers working with whole-plant extracts.
Theodoropoulos calls it “a brutal redistribution of the market: small and medium-sized industrial hemp producers are losing the products in which they invested, while large, vertically integrated medical cannabis companies are placed in a distinctly more advantageous position to fill the resulting gap.”
Put plainly, the commercial winner in this scenario may simply be whoever can strip the plant down far enough to satisfy the wording on the page.
What Are Small Hemp Processors Actually Facing Right Now?
For processors operating on thin margins, “reformulate” is a heavier lift than it sounds. It means:
- Replacing natural full-spectrum and broad-spectrum extracts with CBD isolate, which requires new sourcing, new formulation work, and new supplier relationships
- Writing off existing inventory that no longer qualifies, along with the packaging and labeling built around it
- Commissioning new lab testing to confirm isolate-based products meet the “exclusively CBD” standard
- Absorbing the cost and delay of relabeling every SKU affected by the change
None of this happens instantly, and none of it is cheap. For a larger company, it’s disruptive. For smaller operations without visibility or legal resources, it could be existential.
Is Greece’s CBD Rule Missing an Important Scientific Distinction?
This raises a bigger question worth asking: is it reasonable to regulate trace THC, natural minor cannabinoids, semi-synthetic intoxicants, and ordinary full-spectrum extracts as though they’re interchangeable risks?
They aren’t. Trace THC below detection limits isn’t the same public health concern as a semi-synthetic cannabinoid like HHC, which the original circular specifically calls out by name. CBG and CBC aren’t psychoactive at all. A full-spectrum oil with a fraction of a percent of THC bears little resemblance, chemically or functionally, to an intoxicating product engineered to mimic THC’s effects.
Treating all four categories the same under a closed-list, exclusivity-based standard isn’t a careful public health decision. It’s a blunt instrument that happens to land hardest on legitimate, lab-tested natural extracts while leaving room for well-capitalized isolate producers to fill the gap. If Greek regulators want a framework that actually protects consumers, distinguishing between these categories is a reasonable place to start.
Where Does This Leave Greece’s Hemp Market?
Nothing here is final. This is analysis built on legal interpretation and industry reaction to a circular that’s barely a few weeks old, not a court ruling or a formal ministerial clarification on how “exclusively CBD” will be enforced in practice. But the direction of travel is hard to miss, and it lines up with a larger European pattern.
The EU’s novel foods framework already treats CBD as requiring pre-market authorization, and no such authorization currently exists for cannabinoids in food products. On top of that, the European Food Safety Authority set a provisional safe intake level for CBD at just 0.0275 milligrams per kilogram of body weight this year, roughly 2 milligrams a day for a 70-kilogram adult. That’s far below what the wellness industry has traditionally offered, and it’s already narrowing what a compliant product can even look like.
Greece’s “exclusively CBD” language adds a second, more specific constraint on top of that European squeeze. For hemp businesses, the practical move right now is watching for formal EOF or EFET guidance on how strictly “exclusively” gets interpreted, and treating any full-spectrum or CBG-based inventory as at-risk until that clarity arrives.
Frequently Asked Questions
Not explicitly, but industry analysis suggests it may in practice. Greece’s July legislation defines a legal supplement category as containing “exclusively” CBD. Since full-spectrum oils naturally contain trace THC and minor cannabinoids like CBG and CBN, producers such as KANNABIO say these products may no longer qualify.
CBG’s legal status is unsettled under the current interpretation. Legal analysis cited by HempToday indicates that CBG-based and broad-spectrum products may fall outside Greece’s “exclusively CBD” definition, even when they contain no detectable THC, because they include cannabinoids other than CBD.
CBD isolate contains only cannabidiol with no other cannabinoids, which appears to align with Greece’s “exclusively CBD” requirement. Full-spectrum products contain CBD alongside trace THC and minor cannabinoids like CBG and CBC, which may no longer meet the legal definition of a permitted supplement.
Small and mid-sized processors have typically built their product lines around natural full-spectrum and broad-spectrum extracts. Shifting to CBD isolate requires new sourcing, reformulation, lab testing, and relabeling, costs that larger, vertically integrated companies are better equipped to absorb.
It’s a developing interpretation, not confirmed regulatory guidance. The “exclusively CBD” language comes from legislation passed in July 2026, reinforced by a September 15 Ministry of Health circular. How strictly that language applies to full-spectrum and CBG products hasn’t been formally clarified by Greek authorities.
